You are here » Home » Companies » Company Overview » Ankur Drugs & Pharma Ltd

Ankur Drugs & Pharma Ltd.

BSE: 531683 Sector: Health care
BSE 05:30 | 01 Jan Ankur Drugs & Pharma Ltd
NSE 05:30 | 01 Jan Ankur Drugs & Pharma Ltd

Ankur Drugs & Pharma Ltd. (ANKURDRUGS) - Company History

Ankur Drugs and Pharma Ltd is engaged in contract manufacturing of pharmaceuticals formulations. The company has three manufacturing units: two in Himachal Pradesh and one in Daman. Its business segment includes pharmaceutical formulations in the form of tablets capsules liquid orals oral powder dry syrups ointments insta use suspension form fill and seal (FFS) liquid injectables and dry powder injectables. Its clients include Ranbaxy Laboratories Limited Cipla Limited Sandoz Private Limited Abbott India Limited USV Limited Plizer Limited and Sanofi Aventis.The company is a public limited company listed at Bombay Stock Exchange and National Stock Exchange of India Limited. The company was incorporated in the year 1995.Ankur has to its credit several distinctions. It's in the forefront of contract manufacturing with India's leading and multinational pharmaceutical companies. Ankur's first plant is situated at Daman which is having dedicated block for General and Betalactum products in oral dosage form.The Company has set-up two plants spread across 'dimensions' at Himachal Pradesh in excise and pollution free zone amongst lush green surroundings. The main object behind setting up two units was to cater Domestic and International Market.The company's 400 different formulations of various dosage forms i.e. Tablets Capsules Dry Syrups Liquid Orals Injectables Oinments etc. are currently manufactured in Ankur's multi location manufacturing facilities. Company has already received WHO GMP Certification for both Units at Himachal Pradesh.As of March 31 2010 it had installed capacities of 15720 million tablets 2886 million capsules and 300 million effervescent tablets. During the fiscal year ended March 31 2010 (fiscal 2010) it had a production of 9800 million tablets 2090 million capsules and 157 million effervescent tablets. During fiscal 2010 it had in-house developed mosquito repellant patch from ayurvedic formulations.